

SUN BIOMEDICAL LIMITED

ACN 001 285 230

OFFER DOCUMENT

For a renounceable Rights Issue of one (1) New Share for every one (1) Share held by Shareholders registered at 7.00pm AEDT on 29 October 2009 at an issue price of \$0.001 per New Share to raise approximately \$891,456.

IMPORTANT NOTICE

This document is not a prospectus. It does not contain all of the information that an investor would find in a prospectus or which may be required in order to make an informed investment decision regarding, or about the rights attaching to, the New Shares offered by this document.

This document is important and should be read in its entirety. If you do not understand its contents or you are in doubt as to the course of action you should take, you should consult your stockbroker, accountant or other professional adviser without delay.

If you do not lodge an Entitlement and Acceptance Form together with payment by 5.00pm AEDT on 19 November 2009, you will not be issued New Shares in the Company.

Corporate Directory

Registered Office

TressCox Lawyers
Level 9, 469 La Trobe Street
Melbourne, Victoria, 3000
Ph: 1 300 728 275
Fax: (03) 9642 0382
Email: info@sunbiomed.com

Principal Legal Adviser

TressCox Lawyers
Level 9, 469 La Trobe Street
Melbourne Victoria 3000
Ph: 1 300 728 275
Fax: (03) 9642 0382
Email: info@sunbiomed.com

Directors

Mr Terry Cuthbertson
(Non-Executive Chairman)

Mr Peter King
(Non-Executive Director)

Mr Peter Herd
(Non-Executive Director)

Underwriter and Lead Manager

Patersons Securities Limited
Level 23, Exchange Plaza
2 The Esplanade
Perth, Western Australia, 6000
Ph: (08) 9263 1111
Fax: (08) 9325 5123

Company Secretary

Mr Alfonso Grillo

ASX Code

Shares: SBN

Auditor

Armstrong Partners (Aust.) Pty Ltd
PO Box 86
Suite 21, Level 5 150 Albert Road
South Melbourne VIC 3205
Ph: (03) 9695 5500
Fax: (03) 9696 7259

Share Registry

Computershare Investor Services Pty Limited
GPO Box 52
Melbourne, Victoria, 8060
Ph: 1 300 850 505 (within Australia)
Ph: +61 3 9415 4000 (outside Australia)
Fax: (03) 9473 2500

CONTENTS

OFFER DOCUMENT	1
1. CHAIRMAN'S LETTER	2
2. KEY DATES	4
3. DETAILS OF THE RIGHTS ISSUE	5
4. ADDITIONAL INFORMATION	9
5. RISKS	12
6. ACTION REQUIRED BY ELIGIBLE SHAREHOLDERS	14
7. GLOSSARY	17

1. CHAIRMAN'S LETTER

Dear Shareholder

On 14 October 2009, the Company announced that the Company was to undertake a fully underwritten renounceable Rights Issue to raise approximately \$891,456.

Under the Rights Issue, Shareholders are entitled to subscribe for one New Share for every one Share held as at the Record Date, at an issue price of \$0.001 per New Share. The New Shares will be fully paid and rank equally with the Company's existing Shares on issue. The Rights Issue is fully underwritten by Patersons Securities Limited.

Below is a summary of the key terms of the Rights Issue:

Type of offer	Renounceable Rights Issue
Issue Ratio	1 New Share for every 1 Share held
Issue Price	\$0.001 per New Share
Eligible Shareholders	Shareholders who have a registered address in Australia and New Zealand may apply for New Shares under the Rights Issue. Shareholders who have a registered address outside Australia and New Zealand may not subscribe for New Shares under the Rights Issue.
Discount	The Company's Share closing price on 13 October 2009 (the day before the Rights Issue was announced) was \$0.003. Therefore the Issue Price of \$0.001 represents a discount of approximately 66.67% to this closing price.
Capital Raised	Approximately \$891,456 (before costs of the Rights Issue).
Use of Capital Raised	The funds raised will be used for working capital to identify and assess potential growth opportunities.
New Shares to be issued	891,456,280
Shares on issue following Rights Issue	1,782,912,560
Underwriter	Fully underwritten by Patersons Securities Limited

Eligible Shareholders may also apply for additional New Shares over and above their Entitlement. Shareholders should note that the allocation of additional New Shares will be at the discretion of

the Company and the Underwriter. Should additional New Shares not be allocated, those Eligible Shareholders who have applied for additional New Shares will be refunded their application money (without interest) on those New Shares not allotted. Further details of the Shortfall Facility are included at Section 5.

Important Dates


A detailed schedule of key dates is included in Section 2. However, the following are key dates relating to the Rights Issue that you need to be aware of:

Event	Date
Rights trading commences	23 October
Offer Document and Entitlement and Acceptance Form dispatched to Shareholders	5 November
Rights trading ends	12 November
Closing date for receipt of Entitlement and Acceptance Form	5.00pm AEDT on 19 November

Entitlement

If you were an Eligible Shareholder on the Record Date and would like to take up your Entitlement in whole or in part, you may complete the Entitlement and Acceptance Form accompanying this Offer Document. You should then return the completed Entitlement and Acceptance Form together with your cheque for the number of New Shares you wish to subscribe for in the reply paid envelope to the Company's Share Registry by no later than 5.00pm (AEDT) on 19 November 2009. Alternatively, you may elect to utilise the BPAY® facility which will then not necessitate the return of your Entitlement and Acceptance Form to the Company's Share Registry.

Yours sincerely



Terry Cuthbertson
Chairman

® Registered to BPAY Pty Ltd ABN 69 079 137 518

2. KEY DATES

The following are key dates relating to the Rights Issue that you need to be aware of:

Activity	Date
Announcement of Rights Issue	21 October
Dispatch of notices to Shareholders informing of Rights Issue	22 October
Shares quoted 'ex' rights and rights trading commences	23 October
Record Date	29 October
Offer Document and Entitlement & Acceptance Form dispatched and announcement that dispatch completed	5 November
Rights trading ends	12 November
Securities are quoted on a deferred settlement basis	13 November
Closing date for acceptances	19 November
ASX notified of under subscriptions	24 November
Dispatch of New Share transaction confirmation statements. Deferred settlement trading ends.	27 November

Subject to the Listing Rules, the Directors note that this timetable is indicative only and reserve the right to amend this timetable without notice.

3. DETAILS OF THE RIGHTS ISSUE

3.1. Rights Issue

The offer to subscribe for New Shares under the Rights Issue is made to Shareholders whereby Shareholders may subscribe for one (1) New Share for every one (1) Share held by the Shareholder as at 7.00pm AEDT on 29 October 2009 for an issue price is \$0.001 per New Share (*Offer*).

The Offer will result in the issue of 891,456,280 New Shares (based on the current capital structure of the Company) to raise approximately \$891,456 before the costs of the Rights Issue.

The Offer opens for acceptances on 5 November 2009 and all acceptances and payments must be received by not later than 5.00pm AEDT on 19 November 2009. Application for New Shares must be paid for in full. This date may be varied without notice to Shareholders to the extent such change is in accordance with the ASX Listing Rules.

The Rights Issue is renounceable. This means that Rights may be traded on ASX or otherwise transferred if you do not wish to take up some or all of your Entitlement.

Shareholders who are on the Company's Register at 7.00pm AEDT on 29 October 2009 will receive Rights to acquire 1 New Share for every 1 Share held. Shares acquired on the ASX on or after 23 October 2009 (being the date Shares are quoted 'ex' rights, or such other date set by the Securities Clearing House or ASX) will not receive Rights to acquire New Shares under the Offer.

A Shortfall Facility is also available to Eligible Shareholders who subscribe for their full Entitlement. The number of additional New Shares that may be allocated will not be more than the number of additional New Shares applied for and will be subject to the number of New Shares that become available as a result of other Shareholders not taking up their full Entitlement. Shareholders should note that the allocation of additional New Shares will be at the discretion of the Company and the Underwriter.

Only those Shareholders with registered addresses in Australia and New Zealand are entitled to participate in the Rights Issue and accordingly, only those Eligible Shareholders will be entitled to subscribe for New Shares.

3.2. Applying for New Shares

If you are an Eligible Shareholder, you should read Section 6 detailing the process for applying for New Shares.

If you are not an Eligible Shareholder, you may not apply for New Shares under the Offer.

3.3. **Closing Date and payment for New Shares**

The Closing Date for acceptance of the Entitlement and Acceptance Forms together with Application Monies is 5.00pm (AEDT) on 19 November 2009.

Cheques must be drawn in Australian currency on an Australian bank and made payable to '**Sun Biomedical Limited – Renounceable Rights Issue**' and crossed '**Not Negotiable**'. Shareholders are asked not to forward cash, postal notes or money orders by mail. Receipts for payment will not be issued.

Eligible Shareholders who receive an Entitlement and Acceptance Form may submit payment for New Shares by using BPAY. In order to use BPAY, please follow the instructions set out on the Entitlement and Acceptance Form. Payment via BPAY will not necessitate the return of the Entitlement and Acceptance Form to the Company's Share Registry.

Where Rights have been purchased on the ASX the buyer should contact the broker through whom the purchase was made in order to make an application for New Shares.

3.4. **Allotment of New Shares**

The New Shares applied for by Eligible Shareholders will be allotted and issued on 25 November 2009. Transaction confirmation statements pertaining to those New Shares will also be despatched on 27 November 2009.

Until the allotment and issue of New Shares, Application Moneys will be held by the Company in trust in a separate bank account opened and maintained for that purpose only. Any interest earned on the Application Monies will be for the benefit of the Company and will be retained by the Company irrespective of whether allotment takes place.

3.5. **Rights attaching to New Shares**

From allotment, the New Shares issued pursuant to this Offer Document will rank equally in all respects with existing Shares.

3.6. **Discount**

The Company's Share closing price on 13 October 2009, being the day before the Rights Issue was announced, was \$0.003. Therefore the Issue Price of \$0.001 per New Share represents a discount of approximately 66.67% to this closing price.

3.7. **ASX Quotation**

The Company has applied for Official Quotation on ASX for the New Shares.

3.8. **Foreign Shareholders**

The Company has determined that it is unreasonable to make offers of New Shares to Shareholders with registered addresses outside Australia or New Zealand (*Foreign Shareholders*). This decision was made having regard to the number of Foreign Shareholders, the number and value of New Shares those Foreign Shareholders would have been offered and the cost of and time involved in complying with the legal and regulatory requirements of the jurisdictions in which the Foreign Shareholders are domiciled.

The Directors will offer the Rights which would otherwise have been offered to Foreign Shareholders to Patersons Securities Limited (*Nominee*). If there is a viable market in the Rights and a premium over the expenses of the sale can be obtained, the Nominee will sell the Rights. Any sale will be at prices and otherwise in the manner determined by the Nominee in its sole discretion.

Neither the Company nor the Nominee will be liable for any failure to sell the Rights or to sell the Rights at any particular price. The proceeds of the sale of Foreign Shareholders' Rights will be distributed to Foreign Shareholders for whose benefit the Rights are sold in proportion to their Entitlements (after deducting costs).

If there is no viable market for the Rights, the Entitlements of Foreign Shareholders will be allowed to lapse.

3.9. **Rights Issue is fully underwritten**

The Rights Issue is fully underwritten by the Underwriter, Patersons Securities Limited. The Underwriting Agreement is summarised at Section 4.1.

3.10. **Impact of the Rights Issue**

The issue is a pro rata issue to all Shareholders. Shareholders who take up their Entitlement in full will not, as a result of the Rights Issue, have their percentage shareholding in the Company diluted.

Eligible Shareholders are also invited to apply for additional New Shares arising as a result of any Shareholders not taking up their Entitlement in full. Eligible Shareholders may apply for additional New Shares by completing the section of the Entitlement and Acceptance Form which deals with additional New Shares. Any additional New Shares which are not taken up under the Shortfall Facility will then be available to the Underwriter who may offer those New Shares to investors other than existing Shareholders.

The percentage shareholding of Shareholders who sell any of their Rights or who do not exercise all or part of their Rights will have their percentage shareholding in the Company diluted.

The effect of the Rights Issue on the Company's issued share capital will be as follows:

Issued Capital

Fully paid ordinary shares

Existing fully paid ordinary shares prior to the Rights Issue (as at 21 October 2009)	891,456,280
New Shares to be issued by way of Rights Issue	891,456,280
Total fully paid ordinary shares following Rights Issue	1,782,912,560

Capital Structure following the Rights Issue

Quoted

Fully paid ordinary shares	1,782,912,560
Options exercisable at \$0.02, expiring at 30 November 2010	186,950,656

Unquoted

Exercise price 4.5 cents expiring 31 December 2010	4,000,000
Exercise price 10 cents expiring 30 June 2011	20,000,000
Exercise price 2 cents expiring 15 September 2011	2,000,000

4. ADDITIONAL INFORMATION

4.1. Underwriting

The Company has entered into an Underwriting Agreement with the Underwriter whereby the Underwriter has agreed to fully underwrite the Offer.

The Underwriter may terminate its obligations under the Underwriting Agreement in circumstances typically found in underwriting agreements of this nature. The Underwriter may also terminate the Underwriting Agreement if either the All Ordinaries Index or the All Industrial Index drops by 10% or more from the level as at close of trading on 19 October 2009.

The Company is to pay the Underwriter a management fee of \$40,000, a selling fee of 1% of the amount raised under the Rights Issue, an underwriting commission equal to 5% of the dollar amount being underwritten and GST. The Company must also reimburse the Underwriter for all reasonable expenses incurred by it in connection with the Rights Issue. The Underwriter is responsible for paying sub-underwriting fees to any sub-underwriters.

4.2. Section 708AA of the Act

The Offer is being made without a prospectus on issue. The Rights Issue is permitted without a prospectus having regard to Section 708AA of the Act as the Company has met the requirements of this section and has lodged a Section 708AA Notice with ASX.

4.3. Investment decisions

This Offer Document is an important document and requires your immediate attention. It should be read in its entirety. Any investment decision regarding the Company should be based upon both the information contained in this Offer Document and other documents referred to in this Offer Document. In particular, in considering the Company's prospects, Shareholders should consider carefully the risk factors that could affect the Company's performance. Shareholders should carefully consider these factors in light of their personal circumstances including their financial and taxation circumstances. If you do not understand any part of this Offer Document, you should consult your accountant, stockbroker, solicitor or other professional adviser.

4.4. Taxation

The Board considers that it is not appropriate to provide advice regarding the taxation consequences of subscribing for New Shares under this Offer Document.

The Company and its officers and advisers do not accept any responsibility or liability for any taxation consequences of Eligible Shareholders subscribing for and disposing of New Shares. As a result, Eligible Shareholders should consult their own professional tax advisers in connection with subscribing for New Shares under this Offer Document.

4.5. Use of Rights Issue funds

The funds raised will be used as working capital to identify and assess potential growth opportunities.

4.6. Discretion regarding issue

The Directors may, with the consent of the Underwriter, extend the Closing Date or vary the issue and dispatch date. In the case of an extension, the date Rights trading ends and the dates following the Closing Date may be affected.

The Company reserves the right to close the Offer at any time and refund Acceptance Monies without interest.

4.7. ASX disclosure

The Company has lodged notices with ASX in compliance with its continuous disclosure obligations under the Act and the Listing Rules. Shareholders can view the Company's recent announcements on the ASX website www.asx.com.au.

When considering whether to accept their Entitlement under the Rights Issue, Shareholders should consider the Company's ASX announcements and any risks associated with their personal circumstances. Shareholders should also seek professional advice from their stockbroker, accountant or independent financial adviser in relation to subscribing for their Entitlement.

4.8. Privacy

Shareholder information provided in the Entitlement and Acceptance Form will be made available to the Company and the Company's Share Registry. Shareholders are able to gain access to such information by contacting either of those entities. The information on the Entitlement and Acceptance Form is being collected for the purposes of determining the number of New Shares which the Company should issue to Shareholders and to allow the Company to act in accordance with Shareholders' instructions. Information that is provided in the Entitlement and Acceptance Form is also provided to the Underwriter, printers and mailing houses, ASX and other regulatory authorities. If Shareholders do not provide the information in the Entitlement and Acceptance Form, the Company will not be able to issue New Shares in accordance with the Shareholder's instructions.

To make a request for access or to obtain further information about the Company's privacy policy please contact the Company on +613 9663 1100.

4.9. **Definitions**

Certain words and phrases used in this Offer Document have defined meanings set out in the Glossary in Section 7.

4.10. **Enquiries**

If you have any questions regarding the Offer or your Entitlement, please contact the Company's Share Registry:

Computershare Investor Services Pty Limited
Yarra Falls,
GPO Box 52
Melbourne, Victoria, 8060
Ph: 1 300 850 505 (within Australia)
Ph: +61 3 9415 4000 (outside Australia)
Fax: (03) 9473 2500

Alternatively, contact your stockbroker, solicitor, accountant or other professional advisor.

5. RISKS

An investment in New Shares should be regarded as speculative. A number of risks and uncertainties which are both specific to the Company and of a more general nature may affect the future operating and financial performance of the Company and the value of its shares. Estimates and other forward looking statements are only predictions and are subject to inherent risks and uncertainties which are likely to cause actual values, results, performance or achievements to differ from those predicted. The following risk factors are not exhaustive. If any of the following risks materialise, the Company's business, financial condition and operational results are likely to suffer, the trading price of Company shares may fall and you may lose all or part of your investment.

If you do not understand its contents or you are in doubt as to the course of action you should take, you should consult your stockbroker, accountant or other professional adviser without delay.

5.1. Share market risk

Applicants should be aware that there are risks associated with any securities investment. The market price of the Company's securities may fall as well as rise and will be influenced by international and domestic factors. Listed securities may experience extreme price fluctuations that are often unrelated to the operating performances of the relevant companies. For example, share market conditions are affected by many factors such as:

- (a) general economic outlook;
- (b) interest rates and inflation rates;
- (c) currency fluctuations;
- (d) changes in investor sentiment towards particular market sectors; and
- (e) the demand for and supply of capital.

Neither the Company nor its Directors warrant the future performance of the Company or any return on investment in its securities.

5.2. Future capital requirements

In order to achieve the Company's objectives including possible further acquisitions, the Company will require substantial expenditure. Neither the Company nor its directors can guarantee that the funds raised through the Offer will be sufficient to successfully achieve all the objectives of the Company's overall business strategy.

Should the Company fail to raise funds using either debt or equity after the substantial exhaustion of the net proceeds of this Offer, this could delay or suspend the Company's

business strategy. This could have a material adverse effect on the Company's activities indefinitely.

5.3. **Potential acquisitions**

The Company may acquire or significantly invest in technologies, products and companies. As such, any future acquisitions would be accompanied by the risks commonly encountered in making acquisitions of technologies, products and companies.

Should the Company fail to raise sufficient capital through the issue of Shares pursuant to this Offer Document, the Company may not be able to make further acquisitions.

5.4. **General economic climate**

General economic conditions, movements in interest and inflation rates and currency exchange rates may have an adverse effect on the Company's activities and liquidity. Other factors such as legislative changes and political decisions may have an impact on operating costs.

The Company's future income, asset values and share price may be affected by any of the abovementioned factors.

5.5. **Speculative nature of investment**

The above list of risk factors should not be taken as exhaustive of the risks faced by the Company or by investors in the Company. The above factors, and others not specifically referred to above, may in the future materially affect the financial performance of the Company and the value of the Shares offered under this Offer Document. Therefore, the Shares to be issued pursuant to this Offer carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those Shares.

Shareholders should consider that investment in the Company is speculative and should consult their professional advisers before deciding whether to take up their entitlement.

6. ACTION REQUIRED BY ELIGIBLE SHAREHOLDERS

This Section applies only to Eligible Shareholders.

6.1. What you may do

You have the following options available in respect of the Rights offered to you under the Rights Issue. You may:

- (a) take up all of your Entitlement;
- (b) take up all of your Entitlement and also apply for additional New Shares under the Shortfall Facility;
- (c) take up some of your Entitlement and subscribe for some of the New Shares in respect of your Entitlement;
- (d) sell all or part of your Entitlement (in this case, you should contact your stockbroker or the Underwriter before the close of ASX trading in the Rights, being 19 October 2009); or
- (e) not take up any of your Entitlement.

Because the Rights Issue is renounceable, Shareholders who do not wish to subscribe for some or all of their Entitlement to New Shares can sell their Rights on ASX and hence receive consideration for their sale.

Where a Shareholder elects to not subscribe for their full Entitlement and does not trade their Rights, the Rights will lapse.

6.2. Shortfall Facility

Shares which are not applied for will comprise the available New Shares under the Shortfall Facility. Under the Shortfall Facility, Shareholders who have subscribed for all their Entitlement may, in addition to their full Entitlement, apply for additional New Shares, regardless of their present holding.

The Company, in consultation with the Underwriter, may exercise a discretion to impose restrictions on the number of Shares which can be taken up by any Shareholder under the Shortfall Facility. In exercising this discretion, factors such as the number of applications made and the number of available New Shares will be taken into consideration.

Shareholders applying for additional New Shares under the Shortfall Facility should be aware of the following:

- (a) Shareholders may be allotted a lesser number of additional New Shares than applied for;
- (b) Shareholders shall be bound to accept a lesser number of additional New Shares if required by the Company or the Underwriter;
- (c) Shareholders must accept a refund of money in respect of any additional New Shares applied for but not allotted; and
- (d) no interest will be paid on any money refunded to the Shareholders should the circumstances above occur.

6.3. **Closing Date**

Completed Entitlement and Acceptance Forms should be forwarded to the Company's Share Registry, together with a cheque for the amount due in respect of the number of New Shares applied for (being the number of New Shares applied for multiplied by \$0.001) in the enclosed reply paid envelope by the Closing Date.

Where the total amount payable under an application results in a fraction of a cent, payment must be rounded **up** to the nearest whole cent.

The Closing Date for acceptance of the Entitlement and Acceptance Forms is 5.00pm (AEDT) on 19 November 2009. Cheques must be drawn in Australian currency on an Australian bank and made payable to '**Sun Biomedical Limited – Renounceable Rights Issue**' and crossed '**Not Negotiable**'. Shareholders are asked not to forward cash, postal notes or money orders by mail. Receipts for payment will not be issued.

Eligible Shareholders may submit payment for New Shares by using BPAY. In order to use BPAY, please follow the instructions set out on the Entitlement and Acceptance Form. Payment via BPAY will not necessitate the return of the Entitlement and Acceptance Form to the Company's Share Registry.

Where Rights have been purchased on the ASX the buyer should contact the broker through whom the purchase was made in order to make an application for New Shares.

If you elect to not subscribe for your full Entitlement and do not trade your Rights, the Rights not taken up by you will lapse.

6.4. If you do not wish to take up any of your Entitlement

If you do not wish to take up any of your Entitlement, you are not required to take any action. However, you may sell your Rights on market and hence receive consideration for your sale.

If you elect to not subscribe for any of your Entitlement and do not trade your Rights, the Rights not taken up by you will lapse.

7. GLOSSARY

In this Offer Document, the following terms will have the meanings ascribed to them as follows:

\$	Australian Dollar
Act	<i>Corporations Act 2001</i> (Cth)
Application Monies	Money received by the Company from a Shareholder, being the Issue Price multiplied by the number of New Shares applied for
ASX	ASX Limited (ACN 008 624 691)
Closing Date	Date on which the Offer closes, being 5.00pm AEDT on 19 November 2009, which may be varied without prior notice by the Company
Company	Sun Biomedical Limited (ACN 001 285 230)
Director	A director of the Company
Eligible Shareholder	A person who holds Shares in the Company as at the Record Date with a registered address in Australia and New Zealand
Entitlement and Acceptance Form	The form attached to this Offer Document to be completed by Shareholders when applying for New Shares
Entitlement or Entitlement Shares	The number of New Shares under the Offer each Shareholder is entitled to subscribe for calculated on the basis of 1 New Share for every 1 Share held by the Shareholder at the Record Date
Foreign Shareholders	Shareholders as at the Record Date who do not have registered addresses in Australia or New Zealand
Issue Price	\$0.001 per New Share
Listing Rules	Listing rules of ASX
New Share	The Shares to be issued to Shareholders under the Offer
Nominee	Patersons Securities Limited (ACN 008 896 311)
Offer	The offer of New Shares under the Rights Issue pursuant to this Offer Document
Offer Document	This offer document dated 5 November 2009

Official Quotation	Has the same meaning as “Quotation” in the Listing Rules
Official List	Has the same meaning given to it in the Listing Rules
Record Date	Date on which the Entitlement is calculated, being 29 October 2009, which may be varied without prior notice by the Company
Rights	The renounceable rights to subscribe for one New Share for every one Share held pursuant to this Offer Document
Rights Issue	The pro-rata Entitlement to New Shares under the Offer
Section	A section of this Offer Document
Section 708AA Notice	A notice given by the Company pursuant to section 708AA of the Act
Securities Clearing House	ASX Settlement and Transfer Corporation Pty Limited (ABN 49 008 504 532)
Share	A fully paid ordinary share or a partly paid share in the Company
Shareholder	A person who holds Shares in the Company
Share Registry	Computershare Investor Services Pty Ltd (ACN 078 279 277)
Shortfall Facility	The facility available whereby Eligible Shareholders may, subject to the discretion of the Company and the Underwriter, apply for and be issued with additional New Shares above the Eligible Shareholder’s Entitlement
Underwriter	Patersons Securities Limited (ACN 008 896 311)
Underwriting Agreement	The underwriting agreement dated 20 October 2009 between the Company and the Underwriter